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Activation of Bovine Factor VII by
Hageman Factor Fragments
By Robert Radcliffe, Andranik Bagdasarian, Robert Colman, and Yale Nemerson
During the early events of coagulation of rapid proteolysis of one-chain factor VII
human blood by the intrinsic pathway, to a more active two-chain form. The
factor XII is activated to a form which can amino-terminal sequences of the chains of
activate factor Xl, and is proteolytically activated factor VII were found to be Ala-
fragmented to smaller species (30,000 Asx-Gly- and Ile-Val-Gly-, the same as
daltons and 70,000 daltons) which have were earlier observed after activation of
lost most of the ability to activate factor factor VII by activated factor X. This find-
Xl but which can activate prekallikrein ing indicates that initiation of coagulation
rapidly. The effect of these fragments on by the intrinsic pathway also primes the
factor VII was studied. It was found that extrinsic pathway.
these Hageman factor fragments promoted
T HE INTRINSIC PATHWAY of coagulation is initiated by contact of
Hageman factor (factor XII) with an appropriate surface such as collagen
or kaolin and generation of “activated” Hageman factor (factor XIIa). It is
unclear whether this “activation” involves proteolysis, but it is believed that the
molecular weight of factor XIIa 15 similar to that of factor XII (80,000 dal-
tons).”2 Factor XIIa ￿5 believed to activate factor Xl, leading to eventual co-
agulation,3 and plasminogen proactivator,4’t which leads to generation of
plasmin. Some workers believe that plasminogen proactivator is identical to
prekallikrein.6 Plasmin is thought then to feed back on factor XII and generate
proteolytic degradation fragments of factor XIIa, which have little activity
toward factor XI but which are potent activators of prekallikrein.7’#{176} Kalli-
krein, once formed, also possesses potent ability to fragment factor XII.”2’5”
Two of these degradation fragments have been called prekallikrein activator
(PKA; 30,000 daltons)7’9 and large activator (70,000 daltons).’#{176}’#{176}
In the present study we have examined the effect of these fragments of factor
XIIa on factor VII, a single-chain molecule which, in the presence of tissue fac-
tor, initiates coagulation by the extrinsic pathway.’2”3 It has been shown that
factor VII can be cleaved to a more active two-chain molecule by the action of
factor Xa’3 and thrombin)3”4 It has also been reported that kallikrein,’t ‘￿
plasmin, factor IXa, and Hageman factor fragments’7 increase the activity of
factor VII, although detailed molecular changes have not been investigated.
We found that both PKA and large activator promoted rapid activation of
factor VII with formation of a two-chain form suggesting that initiation of the
intrinsic pathway not only leads to activation of factor XI, plasminogen pro-
activator, and prekallik rein, but also primes the extrinsic pathway.
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MATERIALS AND METHODS
Factors VII, X, and Xa were prepared from bovine plasma as described.13 Factor XII was
prepared from human plasma by the method of Cochrane and Wuepper9 followed by disk gel
electrophoresis.’ ￿ PKA and large activator of prekallikrein were prepared by alcohol and salt
fractionation, and ion-exchange and gel-exclusion chromatography from glass-contacted human
plasma.’#{176} Human brain phospholipid was prepared by the method of Bell and Alton.18 Bovine
brain thromboplastin was prepared by the method of Quick.19
Factor VII was assayed by the method of Nemerson and Clyne.20 Factor XII was assayed by a
modified partial thromboplastin time in the presence and absence of kaolin (I mg/mI).2’ One ml of
normal plasma was defined to contain 100 units of factors VII and XII. Prekallikrein-activating
ability was assayed by measuring the increase in hydrolysis of tosyl arginine methyl ester (TAMe)
(due to released kallikrein) by citrated normal plasma after preincubation with the activator
species. I0￿22
The sources of other reagents and the procedures for analytical and preparative sodium dodecyl
sulfate (SDS) slab gel electrophoresis have been reported.’3 Radioautography of SDS gels of
32P-diisopropylfluorophosphate (D 32 P)-labeled proteins was performed as previously de-
scribed.’3 Amino-terminal sequences were determined by the dansyl-SDS procedure of Weiner
et al.23
RESULTS
The factor XII used in these studies had 30 U/mI of coagulant activity in the
presence of kaolin and 0.3 U/ml in its absence. It also possessed 40 U/ml of
prekallikrein-activating ability, implying the presence of degradation frag-
ments.” When this material was reacted with DF32P and electrophoresed on
SDS-acrylamide gels, radioautography revealed DF32P-containing bands at
30,000 and 70,000 daltons. Approximately equal amounts of these species were
present. No bands were seen by staining with Coomassie blue due to the low
protein concentration (approximately 10 ￿zg/ml). The PKA and large activator
preparations were largely free of factor XII coagulant activity but contained
minor amounts of each other as contaminants.’0 The factor VII preparation
displayed a single band on SDS-acrylamide gel electrophoresis.’3
When factor XII, PKA, or large activator was added to factor VII, factor VII
coagulant activity increased rapidly at rates proportional to the amounts of
added activator. Figure 1 shows the time course of activation by PKA and
Fig. 2 shows the course of activation by varying amounts of factor XII. A simi-
lar family of curves was obtained by the action of a large activator preparation
0
Fig. 1. Activation of factor
VII by PKA preparation. Re-
actions contained 0.25 ml of
0.1 M NaCI, 0.05 M Tris-HCI,
> pH 7.5, 1 mg/mI bovine
serum albumin, and factor VII
(400 U/mI, 2 ￿ig/ml) in
plastic tubes at 37’C. PKA
was added to produce final
concentrations of 17 U/mI
(a), 30 U/mI (a), 75 U/mI
(.),or was not added (a).
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Fig. 2. Activation of factor VII
by factor XII preparation. Reac- ￿
tions contained 0.25 ml of 0.1 M
NaCI, 0.05 M Tris-HCI, pH 7.5,
1 mg/mI bovine serum albumin,
and factor VII (400 U/mI, 2 ￿tg/ml) ￿
in plastic tubes at 37’C. Factor ￿
XII preparation was added to
produce final concentrations of
0.6 U/mI (0.2 ￿zg/ml) (n), 1.2
U/mI (a), 2.4 U/mI ( x ), 4.8
U/mI (a), and 12 U/mI (.), or
was not added (a).
containing equivalent prekallikrein-activating potency. In each case the extent
of activation was dependent only on the starting level of factor VII, and the
degree of activation (40-fold) was the same as was seen after activation with
factor Xa or thrombin.’3 When the rates obtained were extrapolated to the
situation of complete fragmentation of factor XII, approximately at plasma
concentration, a rate of activation of 20-fold per minute was calculated.
When the time course of activation was followed by SDS gel electrophoresis
(Fig. 3) it was observed that after 1 hr of incubation the single-chain factor VII
was fully cleaved to a two-chain species whose peptide chains co-electro-
phoresed with the chains generated by the action of factor Xa on factor VII
(center gel slot). The heavy chain (29,500 daltons) and light chain (23,500
daltons) were found to display amino-terminal sequences of Ile-Val-Gly and
Ala-Asx-Gly-, respectively, the same as found for the chains generated by
activation with factor X5.24 The light chains stained poorly with Coomassie
blue and are not well visualized in the figure. In contrast to the reaction with
factor Xa, the two-chain molecule was not readily destroyed by further cleavage
of the heavy chain by factor XII fragments. This difference was not due to loss
of activator activity, since additions were made at intervals to maintain the
factor XII level.
The effects of possible cofactors and inhibitors on the activation by the
factor XII preparation were studied. The rate of activation of factor VII was
not affected by the presence of kaolin (0.25 mg/rn I), calcium chloride (5 mM),
or calcium chloride (5 mM) plus phospholipids (0.2 mg/ml). Benzamidine
(10 mM) inhibited the reaction rate by 90%. Polybrene (0.5 mg/ml) caused
complete inhibition after a several minute lag period. Trypsin inhibitors from
soybean and bovine pancreas at 100 jzg/ml caused 18% and 12% inhibition,
respectively, of the reaction rate. Pretreatment of the factor XII preparation
with DFP (1 mM or 5 mM) for 16 hr at 4#{176}C had no effect on the coagulant
activity but eliminated the ability to activate factor VII. This finding again im-
plicated the degradation fragments as the activating species.
This conclusion was also supported by experiments performed using human
Hagernan factor kindly supplied by Dr J. Griffin and Dr. C. G. Cochrane of the
Department of Experimental Pathology, Scripps Clinic and Research Founda-
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Fig. 3. Activation of factor VII by
I I I _l￿, I I factor XII preparation (A) At time zero
0 ￿ ￿ ￿ 70 120 I2hrs 22hrs 20 zl of factor XII preparation (30
TIME (mm) U/mI) was added to 1 ml of factor VII
. (0.5 mg/mI) in 0.1 M NaCI, 0.05 M
B . Tris-HCI, pH 7.5, in a plastic tube at
20#{176}C. Additional factor XII was added
. . at 3-hr intervals. (B) At indicated
‘ times aliquots were removed and
heated at 100#{176}C for 3 mm with an
equal volume of 4 M urea and 2%
￿ #{149}#{248}s#{149}b￿ . sodium dodecylsufate (SDS) and
S electrophoresed in a 74% poly-
acrylamide slab gel containing tris-
, #{176} C... acetate buffer, pH 7.5, and 0.1% SDS.
Samples on the right also contained
. 5% 2-mercaptoethanol. The center
sample was a mixture of reduced two-
. chain and three-chain factor VII gen-
. crated by the action of factor X0,
#{149} calcium ions, and phospholipids.
Molecular weight standards were re-
duced bovine serum albumin, oval-
S 0 2 4 8 5 I 551 22hr 02 4 815 1551 22hr ￿ bumin, chymotrypsinogen, and cyto-
25 lOhr 25 lOhr chrome C. Coomassue blue.
tion, La Jolla, Calif. Their factor XII, purified in the presence of inhibitors to
a single electrophoretic band (95%), did not activate factor VII. After brief
preincubation with trypsin and inactivation of the trypsin by a 100-fold excess
of orosomucoid trypsin inhibitor (w/w), activation of factor VII was observed
at a rate of 20-fold per minute using the cleaved factor XII at plasma concen-
tration. The control containing trypsin plus a 100-fold excess of orosomucoid
trypsin inhibitor did not cause activation of factor VII.
When aliquots of the Factor XII preparation were added to citrated bovine
plasma, rapid activation of factor VII was observed for several minutes fol-
lowed by a plateau (Fig. 4), which probably reflected inhibition of the factor
XII fragments by plasma inhibitors such as CIINH.25 The assumed inhibition
took longer at 0#{176}C than at 37#{176}C and the resultant degree of activation after each
addition was therefore greater at 0#{176}C. This difference may reflect the same phe-
nomenon as Gjonnaess’s observation that factor VII was activated in certain
plasmas incubated overnight at 0#{176}C, but not at 20#{176} C.’5
Figure 5 indicates that addition of factor XII to citrated human plasma was
followed by activation of factor VII. Activation of human plasma factor VII
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￿2000
￿I600 /1
Fig. 4. Effect of temperature on ￿ 200
activation of factor VII in citrated bovine ￿ ￿oo “#{176}‘
plasma by factor XII preparation. At 0, ￿ I
2, and 4 hr 15 jzl of factor XII prepara- ‘ 400 -
tion (30 U/mI) were added to 0.25 ml of
citrated bovine plasma at 0 C (a) and 0 ￿ ￿ ￿ ￿ ￿ .
37#{176}C (.), or were not added ( x ). Plastic 0 1 2 3 4 5
tubes were used. TIME (hoursl
35-fold and activation of bovine plasma factor VII 55-fold were obtained.
Factor VII was assayed in the presence of tissue factor. No acceleration of
coagulation was detected when tissue factor was omitted from the assay.
DISCUSSION
The data presented are consistent with the interpretation that fragments of
factor XII cause up to a 55-fold enhancement of the coagulant activity of factor
VII by proteolysis at the same Arg-Ile bond shown to be cleaved by factor X￿
in the presence of calcium ions and phospholipids.24 Calculation indicates that
with reactants at approximate plasma concentrations an activation rate of 20-
fold per minute at 37#{176}C can be expected. This activation rate is similar to that
observed for activation by factor Xa and is rapid enough to be of possible
physiologic significance. It was observed that activation could be produced in
both bovine and human citrated plasma. This finding indicates that the obser-
vations made with purified bovine factor VII can be extrapolated to human
factor VII as well.
Specific assays did not reveal the presence of other coagulation factors in the
factor XII preparation.” The fact that calcium ions and phospholipids did not
enhance the rate of reaction argues against the possibility that contamination
with factor Xa was involved. The action of thrombin would be far too slow’3
to explain the observed rate of activation. Kallikrein’5”6 and plasmin’7 have
been suggested to be activators of factor VII and their presence as minor con-
60
-; 50
Fig. 5. Effect of factor XII
.￿ 40 preparation on factor VII in
citrated bovine plasma (a) and
30 citrated human plasma (.) Addi-
tions of 5 ￿ol of factor XII (30
20 U/mI) were made to 0.3 ml of
t plasma at 0#{176}C at times indicated
s. 0 by arrows up to 3 hr, after which
time 20-￿il aliquots were added.
Corrections were made for dilu-
tion. Plastic tubes were used.
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taminants in the factor XII preparation must be considered. Kallikrein, how-
ever, is strongly inhibited by soybean trypsin inhibitor26 and plasmin has
been shown to rapidly form an inactive stoichiometric complex with both soy-
bean and pancreatic trypsin inhibitors.27 Since these two inhibitors caused only
a weak inhibition of the activation of factor VII when present at high concen-
trations, it is unlikely that kallikrein or plasmin was responsible.
Several lines ofevidence suggest that native factor XII is not an activator of
factor VII: (1) The activation by the factor XII preparation was eliminated by
pretreatment with DF32P, whereas the factor XII coagulant activity remained
intact. (2) When the factor XII preparation was allowed to react with DF32P
and was electrophoresed in SDS-acrylamide gels, radioautography revealed
bands at 70,000 and 30,000 daltons, whereas human factor XII migrates at a
position corresponding to 80,000 daltons.”1 (3) When the activating species
was added to citrated plasma, it was rapidly “inhibited” by a plasma constitu-
ent, in contrast to factor XII, which is stable in plasma. (4) Factor VII in
plasma is in a single-chain form, whereas if plasma factor XII could cause
rapid activation it would exist in its two-chain form. (5) The ability of the
preparations of factor XII, PKA, and large activator to activate factor VII
paralleled their ability to activate prekallikrein, not their coagulant activity.
At the present time, we cannot say which fragmentation product(s) of factor
XII are of physiologic significance. It is clear, however, that proteolysis of
factor XII results in species which activate factor VII.
The present data indicate that the intrinsic pathway and extrinsic pathway
are connected at their initiation points. While the physiologic significance of
this interaction remains to be established, it is clear that the two pathways do
not function in isolation. Fragmentation of Hageman factor appears to gen-
erate enzymes of broad specificity which can initiate the kinin system and the
fibrinolytic system and prime the extrinsic coagulation pathway.
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